XML 114 R70.htm IDEA: XBRL DOCUMENT
v3.22.4

Liabilities related to business combinations and to non-controlling interests (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Business Combinations [Abstract] |
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests | Movements in liabilities related to business combinations and to non-controlling interests are shown below:
(€ million) |  |  | Bayer contingent consideration arising from the acquisition of Genzyme | MSD contingent consideration (European Vaccines business) | Shire contingent consideration arising from the acquisition of Translate Bio | Contingent consideration arising from acquisition of Amunix | Other | Total(a)
Balance at January 1, 2020 |  |  | 156 |  | 385 |  | — |  | — |  | 259 |  | 800 |
Payments made |  |  | (42) |  | (78) |  | — |  | — |  | (2) |  | (122) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)(b) |  |  | 9 |  | 9 |  | — |  | — |  | (53) |  | (35) |
Other movements |  |  | (8) |  | — |  | — |  | — |  | (2) |  | (10) |
Currency translation differences |  |  | (11) |  | (4) |  | — |  | — |  | (13) |  | (28) |
Balance at December 31, 2020 |  |  | 104 |  | 312 |  | — |  | — |  | 189 |  | 605 |
New transactions(c) |  |  | — |  | — |  | 323 |  | — |  | 37 |  | 360 |
Payments made(d) |  |  | (31) |  | (75) |  | — |  | — |  | (152) |  | (258) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)(b) |  |  | (18) |  | 26 |  | 19 |  | — |  | (31) |  | (4) |
Other movements |  |  | — |  | — |  | — |  | — |  | (14) |  | (14) |
Currency translation differences |  |  | 4 |  | 6 |  | 12 |  | — |  | 3 |  | 25 |
Balance at December 31, 2021 |  |  | 59 |  | 269 |  | 354 |  | — |  | 32 |  | 714 |
New transactions |  |  | — |  | — |  | — |  | 156 |  | — |  | 156 |
Payments made |  |  | (29) |  | (79) |  | — |  | — |  | (28) |  | (136) |
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)(b) |  |  | (9) |  | 14 |  | 2 |  | (2) |  | — |  | 5 |
Other movements |  |  | — |  | — |  | — |  | — |  | — |  | — |
Currency translation differences |  |  | 5 |  | — |  | 24 |  | 11 |  | — |  | 40 |
Balance at December 31, 2022 |  |  | 26 |  | 204 |  | 380 |  | 165 |  | 4 |  | 779 |
(a) Portion due after more than one year: €674 million as of December 31, 2022 (€577 million as of December 31, 2021 and €387 million as of December 31, 2020); portion due within less than one year: €105 million as of December 31, 2022 (€137 million as of December 31, 2021 and €218 million as of December 31, 2020). (b) Amounts reported within the income statement line item Fair value remeasurement of contingent consideration, and mainly comprising unrealized gains and losses. (c) Mainly corresponds to the recognition of the Shire Human Genetic Therapies Inc. (Shire) contingent consideration liability of $382 million resulting from the acquisition of Translate Bio in September 2021. (d) The “Other” column mainly relates to the contingent consideration liability due to True North Therapeutics as a result of Sanofi's acquisition of Bioverativ which was settled in the first half of 2021.
Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests | The table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:
December 31, 2022 | Total | Payments due by period
(€ million) | Less than 1 year | From 1 to 3 years | From 3 to 5 years | More than 5 years
Commitments relating to contingent consideration in connection with business combinations(a) | 604 |  | 104 |  | 145 |  | — |  | 355 |
(a) Includes €0.4 billion for the Bayer contingent consideration, €0.2 billion for the MSD contingent consideration.

X
- Definition Business Combinations [Abstract] + References No definition available. + Details
Name: | sny_BusinessCombinationsAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of changes in liabilities related to business combinations and to non-controlling interests. + References No definition available. + Details
Name: | sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration